Roche's Oncology Strategy: The Long Game Comes Into Focus
Executive Summary
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
You may also be interested in...
Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology
Roche used its ASCO investor briefing to highlight its digital and personalized healthcare strategy, including examples of how it’s facilitating R&D and reimbursement – and how that should position it to be an oncology leader in the future.
Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Roche’s proficiency at antibody engineering allows it to construct the next-generation molecules needed to translate scientific insights into therapeutic candidates.
Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Roche’s proficiency at antibody engineering allows it to construct the next-generation molecules needed to translate scientific insights into therapeutic candidates.